Adjuvant Abemaciclib
Oct 14, 2021•17 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
FDA approves 2-years of abemaciclib plus endocrine therapy for high-risk HR+, HER2(-) patients. Quite a bit to discuss about this. Also, FDA expands indications for pembrolizumab (of course) and brexucabtagene autoleucel.
NOTE: A 5cm breast tumor is a T3 lesion, not a T2 as misstated in this episode.
For the best experience, listen in Metacast app for iOS or Android